Dyne Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Dyne Therapeutics, Inc. (DYN) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $2.60 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-02
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.60M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3.87M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5.36M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7.02M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $2.60M 10-K · filed 2026-03-02 |
| 2024-12-31 | $3.87M 10-K · filed 2025-02-27 |
| 2023-12-31 | $5.36M 10-K · filed 2024-03-05 |
| 2022-12-31 | $7.02M 10-K · filed 2023-03-02 |
| 2021-12-31 | $8.85M 10-K · filed 2022-03-10 |
| 2021-09-30 | $9.32M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $7.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |